- Home
- Products
- Customized FluoroAb™
- CEACAM1
- Anti-CEACAM1 MAb (Clone 1)-iFluor® 405 Succinimidyl Ester
Anti-CEACAM1 MAb (Clone 1)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1729)
This product is comprised of an Humanized Anti-CEACAM1 IgG1-Fab' fragment (Clone 1) labeled with iFluor® 405 Succinimidyl Ester. iFluor® 405 Succinimidyl Ester is a Blue-fluorescent dye and it's excitation/emission is 403/427 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- CEACAM1
- Alternative Names
- CEACAM1; carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein); BGP; carcinoembryonic antigen-related cell adhesion molecule 1; BGP1; CD66a; antigen CD66; CD66a antigen; BGPI;
- Overview
- This gene encodes a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. The encoded protein was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.
- Overview
- Humanized Anti-CEACAM1 IgG1-Fab’ fragment (Clone 1)
- Species Reactivity
- Human
- Name
- iFluor® 405 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 403/427
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS1729. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-964 | Anti-CEACAM1 (Arcitumomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-965 | Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-962 | Anti-CEACAM1 (Arcitumomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-963 | Anti-CEACAM1 (Arcitumomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-967 | Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-PVRL4 MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13942)
- Anti-MUC16 MAb (Clone 1)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS7926)
- Anti-MSLN MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5063)
- Anti-IGF1R MAb (Clone 2)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14453)
- Anti-CD6 MAb (Clone 15)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10444)
- Anti-TFPI MAb (Clone 3)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1499)
- Anti-CD19 MAb (Clone 10)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6708)
- Anti-CTLA4 MAb (Clone 6)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1238)
- Anti-CD19 MAb (Clone 28)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13238)
- Anti-CD3E MAb (Clone 13)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13434)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.